Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

EF Hutton Maintains Buy on Anixa Biosciences, Maintains $10 Price Target

Author: Benzinga Newsdesk | September 09, 2024 11:54am
EF Hutton analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

Posted In: ANIX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist